<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4149">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727775</url>
  </required_header>
  <id_info>
    <org_study_id>AMU</org_study_id>
    <nct_id>NCT04727775</nct_id>
  </id_info>
  <brief_title>Antiviral Drugs on the Treatment of SARS-CoV-2</brief_title>
  <acronym>FavRem</acronym>
  <official_title>A Retrospective Study of the Effect of Antiviral Drugs on the Treatment of SARS-CoV-2 COVID19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astana Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astana Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Analyzing the case histories of patients with SARS-CoV2 COVID19 infection and the impact on&#xD;
      the outcomes of prescribing antiviral drugs&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Anticipated">March 20, 2021</completion_date>
  <primary_completion_date type="Actual">January 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>retrospective trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outcome without comlications</measure>
    <time_frame>14 days</time_frame>
    <description>The recovery time will be evaluated with and without antiviral drugs retrospectively in homogeneous groups of patients with SARS-CoV2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>14 days</time_frame>
    <description>Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2</measure>
    <time_frame>14 days</time_frame>
    <description>Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>14 days</time_frame>
    <description>Measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>14 days</time_frame>
    <description>Measure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Complication of Medical Care</condition>
  <condition>Pneumonia, Viral</condition>
  <arm_group>
    <arm_group_label>Complications</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evaluathion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxygen status</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evaluathion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxugen support</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Evaluathion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir</intervention_name>
    <description>Antiviral drugs</description>
    <arm_group_label>Complications</arm_group_label>
    <arm_group_label>Oxugen support</arm_group_label>
    <arm_group_label>Oxygen status</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>Antiviral drugs</description>
    <arm_group_label>Complications</arm_group_label>
    <arm_group_label>Oxugen support</arm_group_label>
    <arm_group_label>Oxygen status</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        main group&#xD;
&#xD;
          -  Patients with COVID19 with medium and easy condition disease&#xD;
&#xD;
          -  take favipiravir/remdisivir control group&#xD;
&#xD;
          -  Patients with COVID19 with medium and easy condition disease&#xD;
&#xD;
          -  not take favipiravir/remdisivir&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients younger 18&#xD;
&#xD;
          -  severe conditionis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aidos Konkaev</name>
      <address>
        <city>Nur-Sultan</city>
        <zip>010000</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aidos Konkaev, PhD</last_name>
      <phone>87475339215</phone>
      <email>konkaev@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Astana Medical University</investigator_affiliation>
    <investigator_full_name>Aidos Konkayev</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Retrospective study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

